Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2023)

Historic Total Non-Current Liabilities for Denali Therapeutics (DNLI) over the last 7 years, with Q4 2023 value amounting to $123.0 million.

  • Denali Therapeutics' Total Non-Current Liabilities fell 7054.31% to $123.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $123.0 million, marking a year-over-year decrease of 7054.31%. This contributed to the annual value of $123.0 million for FY2023, which is 7054.31% down from last year.
  • Latest data reveals that Denali Therapeutics reported Total Non-Current Liabilities of $123.0 million as of Q4 2023, which was down 7054.31% from $118.1 million recorded in Q3 2023.
  • Over the past 5 years, Denali Therapeutics' Total Non-Current Liabilities peaked at $453.0 million during Q4 2020, and registered a low of $118.1 million during Q3 2023.
  • For the 5-year period, Denali Therapeutics' Total Non-Current Liabilities averaged around $289.1 million, with its median value being $295.0 million (2020).
  • As far as peak fluctuations go, Denali Therapeutics' Total Non-Current Liabilities soared by 20140.62% in 2021, and later tumbled by 7161.33% in 2023.
  • Quarter analysis of 5 years shows Denali Therapeutics' Total Non-Current Liabilities stood at $158.0 million in 2019, then soared by 186.81% to $453.0 million in 2020, then decreased by 2.55% to $441.5 million in 2021, then decreased by 5.45% to $417.4 million in 2022, then plummeted by 70.54% to $123.0 million in 2023.
  • Its Total Non-Current Liabilities was $123.0 million in Q4 2023, compared to $118.1 million in Q3 2023 and $118.5 million in Q2 2023.